New drug trial aims to halt diabetic vision loss
NCT ID NCT07489131
Summary
This study is testing if a new drug called AVT29 is as effective and safe as the standard treatment, Eylea HD, for diabetic macular edema, a condition that causes vision loss. About 256 adults with this specific type of vision loss from diabetes will be randomly assigned to receive one of the two drugs. The main goal is to see if AVT29 can improve vision as much as the current standard treatment after 8 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.